Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지
DOI QR코드

DOI QR Code

An Open-Label Study of OROS-Methylphenidate for Neuropsychological Changes in Children and Adolescents with Attention-Deficit Hyperactivity Disorder

주의력 결핍 과잉 행동 환자에서 OROS-Methylphenidate 투여 후 신경심리학적 변화에 대한 개방 연구

  • Kook, So-Dahm (Department of Psychiatry, Myongji Hospital) ;
  • Kim, Joo-Young (Yonsei Junior Clinic) ;
  • Cheon, Keun-Ah (Department of Child and Adolescent Psychiatry, College of Medicine, Yonsei University) ;
  • Jhung, Kyungun (Department of Psychiatry, Konyang University College of Medicine) ;
  • Song, Dong-Ho (Department of Child and Adolescent Psychiatry, College of Medicine, Yonsei University)
  • 국소담 (명지병원 정신건강의학과) ;
  • 김주영 (연세주니어 정신과의원) ;
  • 천근아 (연세대학교 의과대학 정신과학교실 소아청소년정신과) ;
  • 정경운 (건양대학교 의과대학 정신과학교실) ;
  • 송동호 (연세대학교 의과대학 정신과학교실 소아청소년정신과)
  • Received : 2013.07.30
  • Accepted : 2013.09.01
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : Previous studies reported that attention-deficit hyperactivity disorder (ADHD) resulted from a deficit of selective attention and sustained attention. In this study, we assessed the result of methylphenidate-induced changes of the cerebral frontal executive functions in patients with ADHD. Methods : The subjects in this study consisted of 16 ADHD patients whose age ranged from 7 to 12. We used ADHD Diagnostic System (ADS) for the attention improvement, and the Stroop Test for the executive function response to pharmacotherapy with MPH. Results : After pharmacotherapy with methylphenidate for 12 weeks, the study group showed improvement in the clinical aspects through Clinical Global Impression-Severity, ADHD-rating scale and Inattention/Overactivity With Aggression Conner's Parents Rating Scale. In the ADS test, only in auditory task there was a decrease of both the response time and the standard deviation of the response time significantly. In the Stroop Test, there was a decrease in the word task, color task and color-word task significantly. Conclusion : Our results show that psychostimulant medication improves neuropsychological function, including the cerebral frontal executive function. This study implies that we have to consider the improvement of executive function, as well as attention when evaluating the efficacy of treatment.

Keywords

References

  1. Connor DF, Ford JD. Comorbid symptom severity in attention-deficit/ hyperactivity disorder: a clinical study. J Clin Psychiatry 2012; 73:711-717. https://doi.org/10.4088/JCP.11m07099
  2. Lambert NM, Sandoval J. The prevalence of learning disabilities in a sample of children considered hyperactive. J Abnorm Child Psychol 1980;8:33-50. https://doi.org/10.1007/BF00918160
  3. Fischer M, Barkley RA, Smallish L, Fletcher K. Young adult followup of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 2002;30:463-475. https://doi.org/10.1023/A:1019864813776
  4. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1313-1323. https://doi.org/10.1016/j.biopsych.2004.11.024
  5. Noland JS, Singer LT, Short EJ, Minnes S, Arendt RE, Kirchner HL, et al. Prenatal drug exposure and selective attention in preschoolers. Neurotoxicol Teratol 2005;27:429-438. https://doi.org/10.1016/j.ntt.2005.02.001
  6. Indredavik MS, Vik T, Heyerdahl S, Kulseng S, Fayers P, Brubakk AM. Psychiatric symptoms and disorders in adolescents with low birth weight. Arch Dis Child Fetal Neonatal Ed 2004;89:F445-F450. https://doi.org/10.1136/adc.2003.038943
  7. Shaywitz SE, Cohen DJ, Shaywitz BA. The biochemical basis of minimal brain dysfunction. J Pediatr 1978;92:179-187. https://doi.org/10.1016/S0022-3476(78)80001-8
  8. Schneider JS, Sun ZQ, Roeltgen DP. Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys. Pharmacol Biochem Behav 1994;48:235-240. https://doi.org/10.1016/0091-3057(94)90522-3
  9. Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci 2002;3:617-628. https://doi.org/10.1038/nrn896
  10. Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002;288:1740-1748. https://doi.org/10.1001/jama.288.14.1740
  11. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997;121:65-94. https://doi.org/10.1037/0033-2909.121.1.65
  12. Pennington BF, Ozonoff S. Executive functions and developmental psychopathology. J Child Psychol Psychiatry 1996;37:51-87. https://doi.org/10.1111/j.1469-7610.1996.tb01380.x
  13. Schachar R, Mota VL, Logan GD, Tannock R, Klim P. Confirmation of an inhibitory control deficit in attention-deficit/hyperactivity disorder. J Abnorm Child Psychol 2000;28:227-235. https://doi.org/10.1023/A:1005140103162
  14. Biederman J, Monuteaux MC, Doyle AE, Seidman LJ, Wilens TE, Ferrero F, et al. Impact of executive function deficits and attentiondeficit/ hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol 2004;72:757-766. https://doi.org/10.1037/0022-006X.72.5.757
  15. Sonuga-Barke EJ, Sergeant JA, Nigg J, Willcutt E. Executive dysfunction and delay aversion in attention deficit hyperactivity disorder: nosologic and diagnostic implications. Child Adolesc Psychiatr Clin N Am 2008;17:367-384, ix. https://doi.org/10.1016/j.chc.2007.11.008
  16. Park SM, Shin MS. Comparison of executive function in children with ADHD and anxiety disorder. J Kor Acad Child Adolesc Psychiatry 2010;21:147-152. https://doi.org/10.5765/JKACAP.2010.21.3.147
  17. Vance AL, Maruff P, Barnett R. Attention deficit hyperactivity disorder, combined type: better executive function performance with longer-term psychostimulant medication. Aust N Z J Psychiatry 2003;37:570-576. https://doi.org/10.1046/j.1440-1614.2003.01238.x
  18. Snyder AM, Maruff P, Pietrzak RH, Cromer JR, Snyder PJ. Effect of treatment with stimulant medication on nonverbal executive function and visuomotor speed in children with attention deficit/hyperactivity disorder (ADHD). Child Neuropsychol 2008;14:211-226. https://doi.org/10.1080/09297040701220005
  19. Aron AR, Dowson JH, Sahakian BJ, Robbins TW. Methylphenidate improves response inhibition in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2003;54:1465-1468. https://doi.org/10.1016/S0006-3223(03)00609-7
  20. Yoo HY, Kim B, Joung YS, Bahn GH, Song DH, Ahn DH, et al. An open-label study of the improvements in clinical symptoms and neurocognitive functions in Korean children and adolescents with attention-deficit hyperactivity disorder after treatment with metadate CD. J Kor Acad Child Adolesc Psychiatry 2011;22:253-261. https://doi.org/10.5765/jkacap.2011.22.4.253
  21. Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum Psychopharmacol 2009; 24:95-102. https://doi.org/10.1002/hup.1010
  22. Klein C, Wendling K, Huettner P, Ruder H, Peper M. Intra-subject variability in attention-deficit hyperactivity disorder. Biol Psychiatry 2006;60:1088-1097. https://doi.org/10.1016/j.biopsych.2006.04.003
  23. Golden CJ. Identification of brain disorders by the Stroop Color and Word Test. J Clin Psychol 1976;32:654-658. https://doi.org/10.1002/1097-4679(197607)32:3<654::AID-JCLP2270320336>3.0.CO;2-Z
  24. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006;59:829-835. https://doi.org/10.1016/j.biopsych.2005.09.011
  25. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proofof- concept and proof-of-product studies. Arch Gen Psychiatry 2003; 60:204-211. https://doi.org/10.1001/archpsyc.60.2.204
  26. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997;68:2032-2037.
  27. Kim YS, Cheon KA, Kim BN, Chang SA, Yoo HJ, Kim JW, et al. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version- Korean version (K-SADS-PL-K). Yonsei Med J 2004;45:81-89. https://doi.org/10.3349/ymj.2004.45.1.81
  28. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976.
  29. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. A DHD Rating Scale-IV: C hecklists, Norms a nd Clinical I nterpretations. New York, NY: Guilford Press; 1998.
  30. Goyette CH, Conners CK, Ulrich RF. Normative data on revised Conners Parent and Teacher Rating Scales. J Abnorm Child Psychol 1978;6:221-236. https://doi.org/10.1007/BF00919127
  31. Shim MS, Cho SZ, Chun SY, Hong KE. A study of the development and standardization of ADHD diagnostic system. J Korean Acad Child Adolesc Psychiatry 2000;11:91-99.
  32. Stroop JR. Studies of interference in serial verbal reactions. Exp Psychol 1935;18:643-662. https://doi.org/10.1037/h0054651
  33. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006;160:82-90. https://doi.org/10.1001/archpedi.160.1.82
  34. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006;13:e50-e62.
  35. Perwien A, Hall J, Swensen A, Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention- deficit/hyperactivity disorder. J Manag Care Pharm 2004; 10:122-129.
  36. Miyake A, Friedman NP, Emerson MJ, Witzki AH, Howerter A, Wager TD. The unity and diversity of executive functions and their contributions to complex "Frontal Lobe" tasks: a latent variable analysis. Cogn Psychol 2000;41:49-100. https://doi.org/10.1006/cogp.1999.0734